Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects.

MLA

Doroud, Delaram, et al. “Comparative Assessment of a COVID-19 Vaccine after Technology Transfer to Iran from Critical Quality Attributes to Clinical and Immunogenicity Aspects.” Scientific Reports, vol. 14, no. 1, Nov. 2024, p. 26793. EBSCOhost, https://doi.org/10.1038/s41598-024-77331-8.

APA

Doroud, D., Sadat Larijani, M., Biglari, A., Ashrafian, F., Sabouni, T., Eybpoosh, S., Verez-Bencomo, V., Valdés-Balbín, Y., García-Rivera, D., Herrera-Rojas, Y., Climent-Ruiz, Y., Santana-Mederos, D., & Ramezani, A. (2024). Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects. Scientific Reports, 14(1), 26793. https://doi.org/10.1038/s41598-024-77331-8

Chicago

Doroud, Delaram, Mona Sadat Larijani, Alireza Biglari, Fatemeh Ashrafian, Talieh Sabouni, Sana Eybpoosh, Vicente Verez-Bencomo, et al. 2024. “Comparative Assessment of a COVID-19 Vaccine after Technology Transfer to Iran from Critical Quality Attributes to Clinical and Immunogenicity Aspects.” Scientific Reports 14 (1): 26793. doi:10.1038/s41598-024-77331-8.